Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #CRC--Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients whose disease has progres...
Bristol Myers Squibb today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable metastatic...
Faron Pharmaceuticals Ltd. Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine ...
Bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumorsCLEVER-1 targeting is safe and well-tolerated with no serious adverse effectsBexmarilimab induced macrophage activation and increased IFNɣ signaling in patients who achieved disease control and prolonged survival TURKU, Finland and BOSTON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical co
BOTHELL - Seagen Inc. today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA in combination with the antibody-drug conjugate ado-trastuzumab emtansine . The combination showed...